Thursday, July 1, 2021 -- Matt Kaeberlein, PhD, will present the latest research on the topic 100,000 longevity interventions per year: How robotics and AI can get us there in 6 months at the worlds' largest annual Aging Research and Drug Discovery conference (8th ARDD). Dr. Matt Kaeberlein is a Professor of Laboratory Medicine and Pathology at the University of Washington (UW) School of Medicine, with Adjunct appointments in Genome Sciences and Oral Health Sciences.
"A major bottleneck in translational geroscience has been an inability to rapidly screen and identify new interventions, particularly combinations of two, three, four or more small molecules, that are able to robustly increase lifespan and healthspan in preclinical models. Using C. elegans, we are overcoming this obstacle by combining the WormBot with Artificial Intelligence to allow fully automated, high-throughput lifespan analysis with healthspan metrics. Scaling up capacity from where we are today by 20-fold will allow for testing of up to 100,000 longevity interventions per year." said Matt Kaeberlein, PhD, Professor of Laboratory Medicine and Pathology at the University of Washington.
Dr. Kaeberlein's research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers and has been recognized by several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer's Association, the Vincent Cristofalo Rising Start in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology from the Gerontological Society of America (GSA).
Dr. Kaeberlein has been awarded Fellow status with the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the GSA. Dr. Kaeberlein is currently the CEO and Chair of AGE, Past-President of AGE, has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB) and AGE, and has served as Biological Sciences Chair and on Council for GSA. Dr. Kaeberlein is the founding Director of the University of Washington (UW) Healthy Aging and Longevity Research Institute, the Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging at UW, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.